论文部分内容阅读
目的:探讨肌酸激酶B(脑型肌酸磷酸激酶,CKB)在前列腺良性及恶性细胞中的表达差异及临床意义。方法:采用实时定量PCR方法检测CKB在BPH1与LNCaP细胞中的表达差异,采用电泳仪法进行血标本CKB检验,最后采用半定量PCR方法研究CKB与雄激素的相关性。结果:CKB在LNCaP的表达量是BPHl细胞中的12.3倍,血检验发现,CKB在未经内分泌治疗前列腺癌组阳性率(5/10)显著高于前列腺增生组(0/10),差异有统计学意义(P<0.05),内分泌治疗前列腺癌组CKB阳性率(4/37)与前列腺增生组阳性率(0/10)相比差异无统计学意义(P>0.05)。CKB在比卡鲁胺(bicalutamide,Casodex)阻断组LNCaP细胞中的表达明显低于无比卡鲁胺阻断LN-CaP细胞。结论:CKB在恶性细胞中高表达,对未经内分泌治疗前列腺癌患者有一定诊断价值,并且其表达受雄激素的调节,可能在前列腺癌的发生发展中起重要作用。
Objective: To investigate the difference and clinical significance of creatine kinase B (CKB) expression in benign and malignant prostate cells. Methods: The difference of CKB expression in BPH1 and LNCaP cells was detected by real-time quantitative PCR. CKB was detected by electrophoresis. Finally, the relationship between CKB and androgen was studied by semi-quantitative PCR. Results: The expression of CKB in LNCaP was 12.3 times higher than that in BPH1 cells. The blood test showed that the positive rate of CKB in non-endocrine-treated prostate cancer group (5/10) was significantly higher than that in benign prostatic hyperplasia group (0/10) Statistical significance (P <0.05). The positive rate of CKB in endocrine-treated prostate cancer group (4/37) was not significantly different from that in benign prostatic hyperplasia group (0/10) (P> 0.05). The expression of CKB in LNCaP cells in bicalutamide (Casodex) blocking group was significantly lower than that of bicalutamide in blocking LN-CaP cells. CONCLUSION: CKB is overexpressed in malignant cells and may be of diagnostic value in patients with prostate cancer without endocrine therapy. And its expression is regulated by androgen, which may play an important role in the development of prostate cancer.